Vol 27, No 2 (2020)
Technology note — Interventional cardiology
Published online: 2019-09-26

open access

Page views 1455
Article views/downloads 867
Get Citation

Connect on Social Media

Connect on Social Media

SAPIEN 3 Ultra — Design and procedural features of a new balloon-expandable valve

Radosław Parma1, Damian Hudziak2, Grzegorz Smolka1, Radosław Gocoł2, Andrzej Ochała1, Wojciech Wojakowski1
Pubmed: 31565790
Cardiol J 2020;27(2):194-196.

Abstract

Not available

Article available in PDF format

View PDF Download PDF file

References

  1. Solomonica A, Choudhury T, Bagur R. Newer-generation of Edwards transcatheter aortic valve systems: SAPIEN 3, Centera, and SAPIEN 3 Ultra. Expert Rev Med Devices. 2019; 16(2): 81–87.
  2. Daubert MA, Weissman NJ, Hahn RT, et al. Long-Term Valve Performance of TAVR and SAVR: A Report From the PARTNER I Trial. JACC Cardiovasc Imaging. 2016 [Epub ahead of print].
  3. Kapadia SR, Leon MB, Makkar RR, et al. PARTNER trial investigators. 5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet. 2015; 385(9986): 2485–2491.
  4. Hahn RT, Pibarot P, Leipsic J, et al. The Effect of Post-Dilatation on Outcomes in the PARTNER 2 SAPIEN 3 Registry. JACC Cardiovasc Interv. 2018; 11(17): 1710–1718.